TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Oncopeptides AB ( (SE:ONCO) ).
Oncopeptides AB has announced the formation of its Nomination Committee for the 2026 annual general meeting. The committee comprises representatives from the company’s three largest shareholders by voting rights, as well as the Chairman of the Board. This development is significant for Oncopeptides as it ensures shareholder representation in the decision-making process, potentially impacting the company’s strategic direction and governance. The committee’s proposals will be shared in the notice for the annual general meeting and on the company’s website.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides is a Swedish biotech company that specializes in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. Utilizing its proprietary Peptide Drug Conjugate (PDC) platform, the company develops compounds that deliver cytotoxic agents directly into cancer cells. Oncopeptides’ flagship drug is being commercialized in Europe, with partnership agreements extending to South Korea, the Middle East, Africa, and other regions. Founded in 2000, the company employs approximately 80 people and operates in Sweden, Germany, Austria, Spain, and Italy. It is listed on Nasdaq Stockholm under the ticker ONCO.
Average Trading Volume: 3,273,609
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.32B
For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.